You can serve more patients per day.
Reduce staffing strain.
Increase margin per clinical hour.
A next-generation Lipid Nanoparticle (LNP) delivery system designed to protect NAD⁺, bypass key metabolic bottlenecks, and support consistent wellbeing with clinic-ready scalability.
LNP-NAD⁺ enables clinics to move beyond time- and chair-limited IV models toward high-throughput, repeatable dispensing that supports patient retention and predictable recurring revenue.
By eliminating lengthy infusion sessions, practices can treat significantly more patients per day, optimise staff utilisation, and improve operational efficiency, without additional treatment rooms or equipment.
From initial consultation to dispensing, LNP-NAD⁺ requires no more than 15 minutes, compared to over an hour for traditional IV NAD⁺ drips.
END RESULTS: Faster patient turnover, lower overheads, and a materially improved margin per hour of clinic operation.
This is not just a clinical upgrade, it is a scalable business model.
The real problem isn’t dosage. It’s delivery. Many NAD⁺ formats struggle with degradation, first-pass metabolism, and limited cellular
entry. LNP technology is engineered to systematically bypass these barriers through a smarter pharmacokinetic pathway.
Drips. Chairs. Long appointments.
Yesterday’s solution.
But here’s the uncomfortable truth: After the spike, the kidneys clear it. Fast.
The dramatic plasma surge creates a short-lived peak followed by rapid elimination. What patients often experience is a temporary lift, not sustained cellular optimisation.
Meanwhile, your clinic absorbs the cost:
LNP-NAD⁺ is engineered using pharmaceutical-grade lipid nanoparticle technology designed to: